| Recruiting | 3 | 6430 | Europe, RoW | Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto | Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins | Leukemia, Acute Lymphoblastic | 06/27 | 06/32 | | |
NCT03911128: A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia |
|
|
| Recruiting | N/A | 500 | Europe, RoW | Observational | Mats Heyman, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation, NordForsk | Leukemia, Acute Lymphoblastic | 08/28 | 08/30 | | |
